South China Morning Post. Now raising US$60 million in a series B round, Yicura BioMed aims for listing under the city's rules for pre-profit IPOs Hong Kong needs more "patient capital" and more talent capable. Eight years into building a stem-cell and drug-delivery platform, Axiom Biosciences is trying something no American biotech has done: list.